The data indicated that there was no significant difference in the mRNA levels between normal and lung cancer patients, implying that other mechanism(s), such as protein stability or translational activity, might be crucial for the regulation of Sp1 during lung cancer progression. The gene discussed is SP1; the disease is lung carcinoma.